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Kidney histopathology in lethal human
sepsis
Adnan Aslan1,2, Marius C. van den Heuvel3, Coen A. Stegeman4, Eliane R. Popa2, Annemarie M. Leliveld5,
Grietje Molema2, Jan G. Zijlstra1* , Jill Moser1,2 and Matijs van Meurs1,2
Abstract
Purpose: The histopathology of sepsis-associated acute kidney injury (AKI) in critically ill patients remains an
understudied area. Previous studies have identified that acute tubular necrosis (ATN) is not the only driver of
sepsis-AKI. The focus of this study was to identify additional candidate processes that may drive sepsis-AKI. To
do this we immunohistochemically characterized the histopathological and cellular features in various compartments
of human septic kidneys.
Methods: We studied the following histopathological features: leukocyte subsets, fibroblast activation, cellular
proliferation, apoptosis, and fibrin deposition in the glomerulus and the tubulointerstitium in human post-
mortem kidney biopsy tissue. Biopsy tissue samples from 27 patients with sepsis-AKI were collected 33 min
(range 24–150) after death in the ICU. The unaffected part of the kidneys from 12 patients undergoing total
nephrectomy as a result of renal carcinoma served as controls.
Results: Immunohistochemical analysis revealed the presence of more neutrophils and macrophages in the glomeruli
and more neutrophils in the tubulointerstitium of renal tissue from patients with sepsis compared to control
renal tissue. Type II macrophages were predominant, with some macrophages expressing both type I and type II markers.
In contrast, there were almost no macrophages found in control kidneys. The number of activated (myo)fibroblasts was
low in the glomeruli of sepsis-AKI kidneys, yet this was not observed in the tubulointerstitium. Cell proliferation and fibrin
deposition were more pronounced in the glomeruli and tubulointerstitium of sepsis-AKI than in control kidneys.
Conclusions: The extensive heterogeneity of observations among and within patients emphasizes the need to
thoroughly characterize patients with sepsis-AKI in a large sample of renal biopsy tissue from patients with sepsis.
Keywords: Sepsis, Kidney, AKI, Histopathology, Immune cells, Apoptosis, Fibroblast, Fibrin
Introduction
Sepsis is a severe and frequent clinical condition in the
intensive care unit (ICU) with an associated mortality
rate varying between 35 and 50% in septic shock [1–3].
The host response to infection leads to organ failure in
patients with sepsis [1]. One of the severely affected
organs is the kidney, with sepsis being the leading cause
of acute kidney injury (AKI) in critically ill patients [2–
4]. Moreover, patients with sepsis-AKI are twice as likely
to die as patients with sepsis without AKI [5, 6].
For a long time, acute tubular necrosis (ATN) due to
hypoxia together with the severe hyperinflammatory
response were thought to be the main drivers of renal
failure in patients with sepsis-AKI [4]. Renal tubuli have
a marginal oxygen supply combined with high oxygen
consumption, yet a reduction in renal blood flow below
critical limits is not uniformly reported in clinical sepsis-
AKI studies [5]. Additionally, hemodynamic impairment
has not been found to be the main driver of renal failure
in patients with sepsis [6–8]. During the last three
decades numerous clinical trials targeting supposedly
pathophysiological mediators within the devastating cas-
cade of inflammatory mediators in sepsis have failed to
improve patient outcome. As a result, mortality in sepsis
remains unacceptably high [9]. This failure undermines
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the validity of the hypothetical causality of these mediators
in sepsis and underscores the limited understanding of the
pathogenesis of sepsis and resulting organ dysfunction [10].
Recently, an elegant sheep model of gram-negative sepsis
with intensive care treatment, combined with sequential
biopsies, also suggested that hypoxia and inflammation can-
not fully explain sepsis-AKI [11]. Histological data address-
ing morphological damage such as ATN in patients with
sepsis-AKI are scarce [12]. In the past, most data were
acquired from post-mortem studies conducted hours or
even days after death. As a result, tissue autolysis and
post-mortem processes may have hampered patho-
physiological interpretation [13]. However, recently 2
important studies reported histopathological findings
on post-mortem biopsies taken immediately after death
[14, 15]. Collectively, the available human tissue data
also do not support the hypothesis that hypoxia and in-
flammation are the major underlying causes of sepsis-
AKI, since only limited inflammation, coagulation and
cell death have been identified [12, 14, 15]. A better
understanding of the underlying pathophysiological
mechanisms of AKI in patients with sepsis is indispens-
able for the development of a therapy that will improve
outcome [16, 17]. Therefore, renewed orientation on
human tissue with a broader scope might reveal add-
itional pathophysiological mechanisms [13, 18, 19].
The aim of this study was therefore to investigate and
expand the histopathological profiles of the glomerular
and tubulointerstitial compartments in human sepsis-
AKI, including inflammation, coagulation, cell cycle, and
repair using immunohistochemical analysis. Compart-
mentalized detection and quantification of these features
may allow us to set the first steps towards therapeutic
interventions that more specifically target cell subsets
and organ niches in sepsis-AKI.
Materials and methods
Patients
We included 27 patients with sepsis-AKI, aged 18
years or older, who had died from sepsis (Table 1 and
Additional file 1: Table S1 and S2) between January
2013 and January 2015. All patients were classified as
having septic shock and treated accordingly with cura-
tive intention [20]. All patients received one or more
vasoactive drug. Patients were classified according to
the risk, injury, failure, loss, end-stage renal failure
(RIFLE) AKI criteria [21]. “Warm” kidney biopsy tis-
sue samples were obtained from these patients within
33 min (range 24–150) after death. Biopsies were per-
formed in 25 patients within 40 min. Messenger RNA
(mRNA) levels in a subset of these biopsy samples
were previously reported [22, 23]. Exclusion criteria
were pre-existing chronic kidney disease (CKD), active
autoimmune disorders with renal involvement, and
immunosuppressive treatment. CKD was defined in
patients on chronic renal replacement therapy or pa-
tients with known creatinine clearance below 60 ml/
min/1.73 m2. Immediate post-mortem biopsies are
performed by definition in deceased patients. There-
fore, legal regulations for studies in living patients do
not apply. We considered our immediate post-mortem
biopsies a limited autopsy. Full autopsy was also offered to
the relatives of the patients. The limited autopsy was per-
formed by clinicians under the responsibility of the path-
ologist, with the purpose of exploring the cause of renal
failure. Permission and written informed consent for this
limited autopsy was asked for in the final family confer-
ence before or just after death. The limited autopsy pro-
cedure was explained in detail and we explained that we
would try to clarify the cause of death and furthermore,
Table 1 Patient characteristics
Sepsis (n = 27) Control (n = 12)
Age (mean yearS (range)) 67.9 (40–85) 59.5 (20–79)
Sex (female:male) 10:17 7:5
LOS (mean days (range)) 3.6 (1–12)
Comorbidities/Medical history (n)
Hypertension 8 3
Diabetes mellitus 3 1
COPD or asthma 7 4
Coronary disease 5 1
Morbid obesity 2 0
Neurologic 3 1
Renal disease 0 0
Vascular surgery 2 0
Auto-immune disease 4 2





Lost renal function 0
End-stage kidney failure 0
Need for RRT: yes/no 12/15 n.a.




Viral (norovirus and HIV) 2
Fungus/yeast 5
LOS Length of stay, RRT renal replacement therapy, COPD chronic obstructive
pulmonary disease, HIV human immunodeficiency virus, n.a. not applicable
aNumber of patients at respective stages
Aslan et al. Critical Care          (2018) 22:359 Page 2 of 12
that we had a research purpose. An autopsy report of the
routine histological findings was added to the patient chart
and was discussed during a meeting with the family 6 weeks
after ICU admission. Control biopsies were obtained from
patients who underwent total nephrectomy as a result of
kidney cancer. A healthy section of tissue was isolated from
the kidney cortex adjacent to, yet as far away as possible
from the tumor. The Medical Ethics Review Committee
(METC) of the University Medical Center Groningen
(UMCG) reviewed and waived the need for ethics approval
for this study (METc 2011/372).
Harvesting and processing of kidney biopsies
Multiple kidney biopsy tissue samples were harvested
from patients with sepsis under ultrasound guidance,
after introducing the biopsy device (Angiotech, 14
Ga × 20 cm, Tru Core2 Biopsy Instrument, Gainesville,
Fl) through a small (5–7 mm) skin incision. Control
renal cortex tissue was obtained by excising the
unaffected areas of the kidney that had been removed
from patients as a result of renal cell carcinoma. Biop-
sies were taken within 30 min after kidney removal,
which was performed by hand-assisted laparoscopy
(n = 9) or by the trans-peritoneal (n = 2) or trans-lum-
bar procedure (n = 1). Renal biopsy tissues were im-
mediately fixed in 10% formalin fixative for
approximately 24 h, which is the recommended fix-
ation time for biopsy tissue without hampering immu-
nohistochemical staining procedures, and were
subsequently imbedded in paraffin.
Histological evaluation of kidney biopsy tissue
For histopathological assessment, deparaffinized sections
were stained with hematoxylin and eosin (H&E), periodic
acid–Schiff (PAS), and martius, scarlet and blue (MSB).
All sections were evaluated by the same experienced
nephro-pathologist (MvdH) and counted manually (MvdH
and AA). Samples were histopathologically scored manu-
ally following the routine pathology procedure in our hos-
pital and therefore could not be blinded. Glomeruli were
counted and evaluated for sclerosis, glomerulitis, and an
increase in mesangial matrix. Tubuli were evaluated for
tubulitis, atrophy, and ATN. The interstitium was evalu-
ated for inflammation and fibrosis. The microvasculature
was evaluated for intima sclerosis, intima arteritis, arteri-
olar hyaline formation and peritubular capillaritis. Fibrin
deposition was also determined in kidney biopsy tissue.
ATN was scored using the grading system described by
Tavares and coworkers [24] and other scoring methods
are summarized in Table 2.
Immunohistochemical analysis
For immunohistochemical analysis, tissue sections
(4 μm) were deparaffinized and rehydrated, and







• All representative (adequately cross-cut) glomeruli together of 27
patients with sepsis
Sclerotic glomeruli
• Scored positive when total sclerosis of glomerulus is observed
Glomerulitis
• Yes: ≥ 10 leukocytes in glomerular capillaries
• No: < 10 leukocytes in glomerular capillaries
Increase in mesangial matrix
• Stage 0: no mesangial matrix increase
• Stage 1: up to 25% of non-sclerotic glomeruli affected (at least
moderate matrix increase)
• Stage 2: 26–50% of non-sclerotic glomeruli affected (at least
moderate matrix increase)
• Stage 3: > 50% of non-sclerotic glomeruli affected (at least
moderate matrix increase)
Leukocyte subsets
• Number of CD3, CD20, CD68 and neutrophil elastase-positive cells
in glomeruli divided by the total count of glomeruli, reported as
mean number of positive cells/glomerulus
Proliferating cells
• Number of Ki-67 positive cells/glomerulus
Myofibroblasts
• Number of anti-α-SMA positive cells in glomeruli divided by the
total count of glomeruli, reported as mean positive foci/glomerulus
Thrombus formation
• Martius, scarlet and blue positive cells in glomeruli divided by the
total count of glomeruli, reported as mean positive foci/glomerulus
Apoptosis
• Number of Anti-caspase-3 positive cells in glomeruli divided by




• Stage 0: no mononuclear cells in tubules
• Stage 1: 1–4 mononuclear cells/tubular cross-section
• Stage 2: 5–10 mononuclear cells/tubular cross-section
• Stage 3: > 10 mononuclear cells/tubular cross-section
Interstitial inflammation
• Stage 0: no or hardly any interstitial parenchyma covered with
mononuclear cells
• Stage 1: 10–25% of interstitial parenchyma covered with
mononuclear cells
• Stage 2: 26–50% of interstitial parenchyma covered with
mononuclear cells
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endogenous peroxidase activity was blocked following
standard protocols. Samples were immunohistochemi-
cally stained to detect neutrophils (neutrophil elastase),
macrophages (CD68), T lymphocytes (CD3, CD4, CD8),
B lymphocytes (CD20), myofibroblasts (alpha-smooth
muscle actin (SMA)), proliferating cells (Ki-67), and
apoptotic cells (activated caspase 3). Staining was per-
formed in a Benchmark Ultra automated IHC/ISH slide
staining system (Ventana Medical Systems, Roche
Diagnostics, Almere, The Netherlands). This system is
used for diagnostic purposes in our pathology depart-
ment. The staining system and the ready-to-use anti-
bodies were validated by the manufacturer and verified
in our pathology department. Control tissue (appendix
tissue) was routinely added for each staining procedure.
Briefly, antigens were retrieved by boiling the sections in
10mM Tris/1mM EDTA pH 9.0 for 15min. Sections
were incubated with primary antibodies (Additional file 2:
Table S3) for 1 h, and subsequently with properly match-
ing secondary HRP-conjugated antibodies (DAKO, Car-
pentaria, CA, USA) for 45min. Standard washing steps
were performed between incubations. Peroxidase activity
was detected using 3-amino-9-ethylcarbazole (DAKO).
To detect type I and type II macrophages, antigens were
retrieved by boiling the sections for 15min in 0.1M (type I
macrophages) or 10mM (type II macrophages) Tris/1mM
EDTA pH 9.0. Endogenous biotin was blocked using the
avidin/biotin blocking kit (Vector Laboratories, Burlingame,
CA, USA). Sections were sequentially incubated for 1 h at
room temperature (RT) with primary antibodies against hu-
man CD68 and IRF5 to identify type I macrophages, or
Table 2 Scoring methods for the histological evaluation of
kidney biopsies (Continued)
• Stage 3: > 50% of interstitial parenchyma covered with
mononuclear cells
Interstitial fibrosis
• Stage 0: interstitial fibrosis tissue of up to 5% of total area
• Stage 1: mild-interstitial fibrosis tissue of 6–25% of total area
• Stage 2: moderate-interstitial fibrosis of 26–50% of total area
• Stage 3: severe interstitial fibrosis of > 50% of total area
Tubular atrophy
• Stage 0: no tubular atrophy
• Stage 1: atrophy in 0–25% of the tubules
• Stage 2: atrophy in 26–50% of the tubules
• Stage 3: atrophy of > 50% of the tubules
Leukocyte subsets
Number of CD3, CD20, CD68 and neutrophil elastase-positive cells
• Stage 0: absent
• Stage 1: focally present
• Stage 2: diffusely present
Proliferating cells
• Number of Ki-67 positive cells/200 tubular epithelial cells
Myofibroblasts
anti-α-SMA positive cells present in tubulointerstitium
• Stage 0: none
• Stage 1: present in 0–25% of tubulointerstitium
• Stage 2: present in 26–50% of tubulointerstitium
• Stage 3: present in 51–75% of tubulointerstitium
• Stage 4: present in > 75% of tubulointerstitium
Thrombus formation
• Number of martius, scarlet and blue total positive foci/2 mm2
Apoptosis
Number of Anti-caspase-3 total positive cells present in tubulointerstitium
• Stage 0: absent
• Stage 1: present in 0–10% of total interstitial cells
• Stage 2: present in 11–50% of total interstitial cells
• Stage 3: present in > 50% of total interstitial cells
Blood vessels
Arteriolar intima sclerosis
• Stage 0: no chronic vascular changes
• Stage 1: vascular narrowing of up to 25% luminal area of arteries
fibro-intimal thickening
• Stage 2: vascular narrowing with 26–50% luminal area of arteries
fibro-intimal thickening
• Stage 3: vascular narrowing with 26–50% luminal area of arteries
fibro-intimal thickening
Arteriolar hyaline
• Stage 0: no PAS-positive hyaline thickening
• Stage 1: mild-to-moderate PAS-positive hyaline in at least one arteriole
Table 2 Scoring methods for the histological evaluation of
kidney biopsies (Continued)
• Stage 2: moderate-to-severe PAS-positive hyaline thickening in
more than one arteriole
• Stage 3: severe PAS-positive hyaline thickening in many arterioles
Intima arteritis
• Stage 0: no arteritis
• Stage 1: mild-to-moderate intimal arteritis in at least one arterial
cross-section
• Stage 2: severe intima arteritis with at least 25% luminal area lost
in at least one arterial cross-section
• Stage 3: arterial fibrinoid change and/or transmural arteritis with
medial smooth muscle necrosis with lymphocytic inflammation
Peritubular capillaritis
• Stage 0: < 10% of capillaries contain inflammatory cells
• Stage 1: > 10% of capillaries contain inflammatory cells, 3–4
mononuclear cells in peritubular capillary lumen
• Stage 2: > 10% of capillaries contain inflammatory cells, 5–10
mononuclear cells in peritubular capillary lumen
• Stage 3: if > 10% of capillaries contain inflammatory cells, > 10
mononuclear cells in peritubular capillary lumen
PAS periodic acid–Schiff, SMA smooth muscle actin
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with primary antibodies against human CD68 and CD163
to identify type II macrophages [25]. Sections were subse-
quently incubated for 1 h at RT with goat anti-rabbit-
alkaline phosphatase (DAKO) and goat anti-mouse-HRP
(DAKO) for type I macrophages, or goat anti-mouse
IgG3-Biotin and goat anti-mouse IgG1-HRP (Southern Bio-
tech, Birmingham, AL 35260, USA) for type II macro-
phages. Sections stained for type II macrophages were
incubated with streptavidin-alkaline phosphatase (DAKO)
after washing. Alkaline phosphatase and peroxidase activity
were detected using the BCIP/NBT kit (Thermo Fisher Sci-
entific, Waltham, MA, USA) and the NovaRed kit (Vector
Laboratories), respectively. Sections were counterstained
with Mayer’s hematoxylin (Merck, Darmstadt, Germany),
mounted and scanned using a Hamamatsu Nanozoomer
2.0 HT (Hamamatsu Photonics, Hamamatsu, Japan). Rep-
resentative images were captured at x 40 magnification.
Statistical analysis
Data were analyzed by the two-tailed Mann–Whitney
test using Graphpad Prism software v7 (GraphPad Prism
software Inc., San Diego, CA, USA) . Differences were
considered significant when the p value was < 0.05.
Results
Histopathological characterization
We first evaluated 926 glomeruli from the kidney biopsy
tissues for signs of glomerulosclerosis, glomerulitis, and
mesangial matrix expansion. All glomeruli were consid-
ered representative. The number of glomeruli differed
per individual biopsy (range 11–85) but was not signifi-
cantly different between patients with sepsis and control
subjects (data not shown). Only a few glomeruli (31/
926) in renal biopsies from patients with sepsis had
sclerotic changes (Additional file 2: Table S4). Glomeru-
litis was absent and an increase in mesangial matrix was
sporadically noted in the glomeruli in samples from pa-
tients with sepsis-AKI.
Tubulitis, defined as the presence of inflammatory
cells in the tubular wall, was absent. However, interstitial
inflammation was observed in two patients, fibrosis in
seven, and tubular atrophy in eight patients with
sepsis-AKI (Additional file 2: Table S4). Leukocytes were
predominantly located within the peritubular capillaries.
ATN was discontinuously distributed in parts of the
renal biopsy from 24/27 patients with sepsis and when
present was in the range of 5–20% of the total tissue
area (Additional file 2: Table S5). Most of these patients
had morphology stage 2 ATN, where vacuolization,
tubular edema, epithelial flattening, and some apoptotic
tubular cells were present. Twelve patients with sepsis
received renal replacement therapy (RRT) during their
stay in the ICU.
Vascular intima sclerosis was observed in 20 sepsis bi-
opsy samples (stage 1, n = 13; stage 2, n = 7; Additional
file 2: Figure S1). Arteriolar hyaline formation was ob-
served in 14 patients (stage 1, n = 12; stage 2, n = 2). In-
tima arteritis was absent. Histopathological changes
were absent in control biopsy tissues.
Infiltration of inflammatory cells
Since inflammation is a classic hallmark of sepsis, we inves-
tigated whether there was inflammatory cell infiltration
within the glomerular and tubulointerstitial compartments
of the kidney in sepsis-AKI. There were significantly
more neutrophils (p < 0.0001; Fig. 1 A-C) and macro-
phages (p < 0.0001; Fig. 1 D-F) within the glomeruli in
sepsis-AKI compared to controls. Glomerular infiltra-
tion of CD3-positive T lymphocytes (Fig. 1 G-I) and
B-lymphocytes (Fig. 1 J-L) was low and did not differ be-
tween sepsis-AKI and control samples. As a consequence,
the CD4/CD8 ratio within the glomeruli could not be
determined.
There was significantly more neutrophil infiltration in
the tubulointerstitium in sepsis-AKI (p < 0.0001; Fig. 2
A-C), paralleling the glomerular findings. However, in
contrast to observations in the glomerulus, macrophage
infiltration was similar in both sepsis-AKI and controls
(p = 0.19; Fig. 2 D-F). Moreover, there was no difference
in T lymphocyte (Fig. 2 G-I) and B lymphocyte counts
(Fig. 2 J-L) in sepsis-AKI and controls. There were more
neutrophils in the peritubular capillaries in sepsis-AKI
compared to controls, but no difference was found in
lymphocyte (T and B) or macrophage counts (Fig. 2 D-L).
Intrarenal presence of repair cells
Since we found increased numbers of macrophages in
the glomeruli in sepsis-AKI compared to control bi-
opsy tissues, we proceeded to investigate whether
these cells participate in tissue destruction or renal re-
pair. Macrophages can be classified into subtypes, with
type I being involved in inflammation and tissue de-
struction, and type II in tissue repair [26–29]. Macro-
phage subtype analysis in the glomeruli in samples
indicated that patients with sepsis predominantly had
type II macrophages (Fig. 3A). Some macrophages in
the glomeruli and tubulointerstitium from 12 patients
with sepsis-AKI expressed both type I and type II
markers (Fig. 3B).
We additionally investigated whether α-SMA-expressing
myofibroblasts, involved in scar formation, were present.
There were significantly fewer myofibroblasts in the glom-
eruli in samples from patients with sepsis-AKI compared
to controls (p < 0.0025; Fig. 4 A-C). There was no differ-
ence in the number of α-SMA-positive cells in the
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tubulointerstitium in sepsis-AKI and control kidneys
(Fig. 5A, B, and C).
Proliferation and apoptosis in renal sepsis
Pursuing further the question of renal damage and re-
pair, we investigated whether cell proliferation and apop-
tosis would be prominent in the kidney in patients with
sepsis-AKI. There were significantly more proliferating
cells in both the glomeruli (p < 0.0001; Fig. 4 D-F), and
the tubulointerstitium (p < 0.0001; Fig. 5 D-F) in sepsis-
AKI than in controls.
Apoptotic cells were virtually absent in the glomeruli
in sepsis-AKI (in total 3 apoptotic cells/26 patients)
and controls (Fig. 4 G-I). In contrast, there were signifi-
cantly more tubulointerstitial apoptotic cells in sepsis-
AKI compared to control renal tissue (p < 0.001; Fig. 5
G-I). However, apoptotic cells were absent in the tubu-
lointerstitium in samples from four patients with
sepsis-AKI. We only found apoptotic cells (10–50%) in
one control patient.
Fibrin deposition
The formation of microvascular fibrin deposition due to
reduced blood flow and/or endothelial activation might be
another deleterious event in sepsis-AKI. Fibrin-stained
thrombi were identififed in the glomeruli in sepsis-AKI
(p < 0.0002), but not in controls (Fig. 4 J, K). One patient
with sepsis had signs of disseminated intravascular coagu-
lation with abundant fibrin deposition.
Fibrin-stained thrombi in the tubulointerstitium were
predominantly present in the peritubular capillary net-
work in 16/27 patients with sepsis-AKI (p < 0.0002; Fig. 5
J-L). Some patients had abundant capillary fibrin depos-
ition. Fibrin deposition was absent in the peritubular ca-







Fig. 1 Leukocyte infiltration in the glomeruli. Leukocyte subsets were immunohistochemically detected in kidney biopsy samples using specific
antibodies (Additional file 2: Table S3: Primary antibodies) and scored according to Table 2. Leukocyte subsets were counted and divided by the
number of glomeruli per patient. Neutrophils (a, b), macrophages (d, e), T lymphocytes (g, h), and B lymphocytes (j, k) were observed in the
glomeruli in kidney tissue from control patients (a, d, g, j) and patients with sepsis (b, e, h, k), and mean leukocyte counts were determined
(c, f, i, l). Black arrows show positively stained leukocytes of various subsets. *Statistically significant. Black lines are medians (c, f, i, l). Red scale bar = 50 μm
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Discussion
The failure of clinical trials that aim to improvwe the out-
come of patients with sepsis-AKI stresses the need for a
more detailed understanding of the pathophysiological pro-
cesses underlying the development of human sepsis-AKI.
The aim of this study was therefore to investigate the
missing histopathological information on the glomeru-
lar and tubulointerstitial compartments in sepsis-AKI,
such as renal inflammation, fibrin deposition, cell pro-
liferation, and repair.
The results from our study corroborate findings from
recent animal and human studies that show that
sepsis-AKI cannot be explained solely by morphological
changes. The landmark study by Takasu and colleagues
showed that tubular injury in sepsis was common but
focal [14]. Moreover, in a sheep model in which sepsis
was induced by continuous intravenous infusion of live
bacteria, the anatomical structure of the kidney was in-
tact [30]. We found renal tubular damage was unequally
distributed and limited in sepsis-AKI. These findings
agree with the Takasu study and support the premise
that tubular damage cannot fully explain the renal func-
tion impairment often found in patients with sepsis [14].
Moreover, our findings also support those found by Ler-
olle and colleagues in which they demonstrated that AKI
in 19 patients with sepsis was associated with intense in-
filtration of glomeruli, interstitial capillaries, and occa-
sionally tubular lumens, by predominantly monocytic
leucocytes [15].
Interestingly, the glomerular architecture was hardly af-
fected in sepsis-AKI. While structural defects were not ap-





Fig. 2 Leukocyte infiltration in the tubulointerstitium. Leukocyte subsets were immunohistochemically detected in kidney biopsy samples using
specific antibodies (Additional file 2: Table S3: Primary antibodies) and scored according to Table 2. Neutrophils (a, b), macrophages (d,
e), T lymphocytes (g, h), and B lymphocytes (j, k) were observed in the interstitium in kidney samples from control patients (a, d, g, j)
and patients with sepsis (b, e, h, k), and mean leukocyte counts were determined (c, f, i, l). T lymphocytes, B lymphocytes, and macrophages were
quantified using an arbitrary score (0 = absent, 1 = focal, 2 = diffuse; c, f, i). For neutrophils, absolute cell counts were determined per high power field
(HPF). Black arrows show stained leukocytes of various subsets. *Statistically significant difference. Black lines are medians (c, f, i, l). Red scale bars = 50 μm
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permeability, one of the determining factors of glomerular
filtration, may explain the decreased glomerular filtration
rate in these patients. Our previous studies identified al-
tered mRNA levels of the endothelial molecules regulating
vascular permeability in this cohort of patients [22, 23],
and in animal models of lipopolysaccharide (LPS)-induced
AKI [23].
Although apoptosis is considered one of the main
mechanisms of tubular damage in AKI, only 21 of the 102
experimental studies on sepsis-AKI focused on apoptosis
[31]. In these studies, 158/170 animals had tubular epithe-
lial cell apoptosis. In previous studies of patients with sep-
sis there were only slight increases in the amount of
apoptotic tubulointerstitial cells [12, 13], or the absence
thereof [32], suggesting a limited role for apoptosis in sep-
sis. Lerolle and colleagues observed apoptosis of tubular
cells and occasionally glomerular cells in patients with
sepsis [15]. In contrast, in sepsis-AKI we identified a vary-
ing (up to high) extent of apoptosis in the tubulointersti-
tium but not in the glomeruli. Our findings, and the
discrepancy between animal and human studies, suggest
that the role of apoptosis in the tubulointerstitial compart-
ment needs to be revisited by expanding these types of
studies in human AKI before rightful conclusions on its
role in AKI can be reached.
Local microvascular thrombosis, a possible conse-
quence of low flow and/or microvascular endothelial
activation [33], might be another mechanism propa-
gating tissue damage in sepsis-AKI. We found low
amounts of fibrin deposition in the glomeruli, similar to
Lerolle et al., who observed glomerular fibrin depositions
in only 1/19 patients with sepsis [15]. In contrast, while
we found abundant fibrin deposition in the peritubular ca-
pillaries, these authors report partial or complete thrombi
in the afferent arterioles in four patients, but no significant
fibrin deposition in the peritubular capillary system [13].
Similarly, Takasu et al. did not find fibrin deposition in
peritubular capillaries in post-mortem kidneys from pa-
tients with sepsis [14].
Among the cellular players held responsible for tissue
damage in sepsis-AKI, neutrophils are the first to infil-
trate the tissues. Neutrophil blockade or depletion in
experimental animal models have varying results in
preventing AKI [34–36]. Here, we found a notable but
limited number of neutrophils in the glomeruli and
tubulointerstitium, including in the peritubular capillar-
ies. However, no renal cell injury could be attributed to
this neutrophil influx. Lerolle et al. reported that neu-
trophil infiltration was limited to the peritubular capil-
laries [15]. Neutrophil function is ambiguous as these
cells are also required for tissue regeneration [34, 37–
39]. Which neutrophil function prevails in human
sepsis-AKI is an important future research focus.
Lymphocytes play an important role in the cytokine
storm characterizing sepsis. In murine endotoxemia, T
lymphocytes were shown to be modulators of kidney func-
tion and responsible for renal neutrophil recruitment [40].
Moreover, T-lymphocytes are important in the develop-
ment of AKI in experimental ischemia reperfusion injury
(IRI) [41]. T lymphocytes were not found to be important
in sepsis-AKI in our study, as these cells hardly invaded
the kidney. The role of B lymphocytes in sepsis-AKI has
A B
Fig. 3 Macrophage subtypes in sepsis with acute kidney injury. Using specific antibodies (Additional file 2: Table S3: Primary antibodies) and scored
according to Table 2A,: total macrophages (CD68) and macrophage subtypes (type I: IRF-5, type II: CD163) were immunohistochemically detected and
quantified in the glomeruli in kidney samples from patients with sepsis and controls. a Representative picture of a tubular region of a biopsy from a
patient with sepsis to illustrate the morphology of an intermediate macrophage. Black arrow: type II macrophage in the peritubular capillary (CD163-
positive). White arrow: “intermediate” macrophage with double staining positive for IRF-5 (type I macrophage) and CD163 (type II macrophage) in the
peritubular capillary (b). *Statistically significant differences. Black lines are medians T, tubulus
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not been studied extensively. The limited experimental
evidence available suggests that B lymphocytes may slow
down or limit the repair process of the kidney after an is-
chemic insult. Moreover, B-lymphocyte deficiency was
shown to be protective against ischemia reperfusion injury
[42, 43]. We hardly found any B lymphocyte infiltration in
the kidneys of patients with sepsis-AKI. Together these
findings suggest that inflammatory damage mediated by B
lymphocytes or T lymphocytes seems to play a minor role
in human sepsis-AKI. Nevertheless, functional contribu-
tions of these cells cannot be excluded in this observa-
tional study.
The dual role of macrophages in damage and repair in
sepsis-AKI is elusive. Renal mononuclear phagocytic cells
consist of different subtypes, of which type I macrophages
are involved in inflammation and tissue destruction, while
type II macrophages attenuate the inflammatory response
and are active during tissue repair [26, 27, 29]. We ob-
served an accumulation of macrophages of both subtypes
around the glomeruli and in the glomerular capillaries,
but not in the tubulointerstitium of patients with sepsis-
AKI. The immediate vicinity of both macrophage subtypes
may suggest inflammation and repair being simultan-
eously active in time and space. Type II macrophages in
sepsis-AKI glomeruli may originate from the systemic cir-
culation, but also from activated, proliferating local cells
[44]. We also found occasional macrophages expressing
markers of both macrophage subtypes. A similar observa-
tion was previously described in the kidneys of rats with
glycol-induced rhabdomyolysis [45]. These cells were pro-
posed to transition from type I to type II and were shown
to increase in numbers during recovery [45].
We also investigated cell proliferation as a marker of tis-





Fig. 4 Proliferation, fibrin deposition and apoptosis in the glomeruli. Markers for tissue repair and fibrin deposition were immunohistochemically
detected in kidney biopsy samples using specific antibodies (Additional file 2: Table S3: Primary antibodies) and scored according to Table 2.
Myofibroblasts (alpha-smooth muscle actin (SMA; a, b), cell proliferation (Ki-67; d, e), apoptosis (caspase 3; g, h), and fibrin deposition (martius,
scarlet, and blue; j, k) were detected in the glomeruli in samples from control patients (a, d, g, j) and patients with sepsis (b, e, h, k) and quantified (c,
f, i, l) per podocyte per patient or per glomerulus per patient. Black arrows show representative staining. *Statistically significant difference. Black lines
are medians (c, f, i, l). Red scale bar = 50 μm
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and tubulointerstitium of sepsis kidneys, concurring with
the findings of Takasu et al. [14]. Although the identity of
proliferating cells was not explored, their presence
suggests increased regeneration of renal tissue as a mech-
anism of repair. Interestingly, the amount of α-SMA-
expressing myofibroblasts, which initially contribute to re-
pair through matrix deposition, was reduced in sepsis-AKI
glomeruli and unchanged in the tubulointerstitium.
Sandbo et al., identified inhibition of α-SMA expression at
the protein and mRNA level in LPS-stimulated vascular
smooth muscle cells of the human aorta, human coron-
ary artery, and rat aorta [46]. They found that de-
creased levels of α-SMA correlate with diminished
cellular contractile function. Renal scar tissue formation
and fibrosis was not abundant in sepsis-AKI although
obviously, long-term effects were not studied. The role
of repair mechanisms in sepsis-AKI is understudied but
preliminary data showing signs of overactivity and un-
deractivity justify further research.
The strength of this current study lies in the early
retrieval of kidney biopsy tissues directly post mortem,
minimizing the influence of autolysis on subsequent
analyses. Indeed, our current and previous studies and
studies by others [22, 23, 47, 48] show the feasibility of
advanced immunohistochemical, mRNA, proteomic, and
metabolomic analyses of these biopsies. When inte-
grated, the resulting datasets will allow better and exten-
sive patient characterization and will hopefully pave the
way towards precision and even personalized medicine
in sepsis-AKI [19].
Despite this future promise, our study has limitations,
mainly the heterogeneity of patients with sepsis-AKI
and therefore the number of included patients. To correl-





Fig. 5 Proliferation, fibrin deposition and apoptosis in the tubulointerstitium. Markers for tissue repair and fibrin deposition were immunohistochemically
detected in kidney biopsy samples using specific antibodies (Additional file 2: Table S3: Primary antibodies) and scored according to Table 2. Myofibroblasts
(alpha-smooth muscle actin (SMA); a, b), cell proliferation (Ki-67; d, e), apoptosis (caspase 3; g, h), and fibrin deposition (martius, scarlet, and blue; j, k) were
detected in the interstitium in samples from control patients (a, d, g, j) and patients with sepsis (b, e, h, k) and quantified (c, f, i, l). Caspase staining was
quantified using an arbitrary score (0, absent; 1, > 0–10% cells positive; 2, > 10–50% cells positive; 3, > 50% cells positive). Black arrows show representative
staining. *Statistically significant difference. Black lines are medians (c, f, i, l). Red scale bar = 50 μm
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clinical characteristics of our patients and draw meaning-
ful conclusions is not possible. Large data and tissue banks
will be required for multivariate analyses. Most patients
with sepsis are relatively old and vary widely in clinical
presentation. Comorbidities and causative microorgan-
isms influence renal pathophysiology. Additionally, some
patients may have had unknown previous renal disease.
We must emphasize that the time between the start of
sepsis and death varied considerably between patients.
Additionally, the biopsies were taken after a prolonged,
variable process of illness and dying, both of which might
have interfered with the observed AKI-related changes.
We only studied biopsy tissues from deceased patients,
which confines our results to the sickest patient group.
Control patients have comorbidity as well, and the surgi-
cal procedure to procure the kidney with clamping of the
renal artery might have already induced histopathological
changes [49]. The choice of control group can be debated.
Furthermore, it is of note that all biopsies were reviewed
by one experienced renal pathologist which improves
consistency but interobserver variability is well-known
among pathologists. Moreover, the histopathologic scoring
followed the routine pathology procedure in our hospital
and therefore could not be blinded, which may have intro-
duced some observer bias. We also do not know whether
our pathophysiological findings in septic kidneys are the
effect of renal processes or processes elsewhere in the
body. Our observations described here might be an epi-
phenomenon, which makes the question “What causes
renal function loss in sepsis?” even more enigmatic.
Conclusion
Our study investigating the histopathology of sepsis-AKI
revealed heterogenic pathophysiological processes among
patients. No one pathogenic mechanism can be singled
out. Our results imply a spectrum of overactive and un-
deractive biological processes.
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